Format

Send to

Choose Destination
Clin Immunol. 2010 Oct;137(1):1-4. doi: 10.1016/j.clim.2010.05.007. Epub 2010 Jun 8.

Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease.

Author information

1
Children's Cancer Research Institute, Zimmermannplatz 10, A-1090, Vienna, Austria. birgit.juergens@ccri.at

Abstract

Chronic granulomatous disease (CGD) is characterized by a disability to produce reactive oxygen intermediates (ROI) caused by a defect of phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. A hyperinflammatory response to immune activation has been reported to contribute to the pathology of CGD. The tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) is considered critical for regulating immune responses and suppression of inflammation. IDO is generally believed to require ROI for enzymatic activity and was found to be inactive in murine CGD. Here, we report that, strikingly, in human CGD IDO metabolic activity is intact. Monocyte-derived dendritic cells generated from CGD patients, harbouring X-linked and autosomal recessive forms of CGD, and from healthy controls produced similar amounts of the tryptophan metabolite kynurenine upon activation with lipopolysaccharide and interferon-γ. Thus, in humans, ROI apparently are dispensable for IDO activity. Hyperinflammation in human CGD cannot be attributed to disabled IDO activation.

PMID:
20570568
PMCID:
PMC2946558
DOI:
10.1016/j.clim.2010.05.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center